Compounds that are S1P modulating agents and/or ATX modulating agents

1. A compound represented by formula (I):

or a pharmaceutically acceptable salt thereof, wherein:

one of A 4 and A 5 is CH and the other is CR 4 ;

R 1 is a C 6-20 alkyl, or a cyclohexyl which is optionally substituted with one R 6 ;

R 4 is a group represented by the following formula:

“ ” represents the point of attachment;

R 6 , for each occurrence, is independently selected from the group consisting of C 1-6 alkyl, C 1-6 haloalkyl, C 3-8 cycloalkyl and phenyl;

R 10 is hydrogen or a C 1-6 alkyl;

p is 0 or an integer from 1 to 6; and

(i) m is 0; and

R 5 is selected from the group consisting of:

or

(ii) m is 1; and

R 5 is cyclobutylene, cyclopentylene or cyclohexylene.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is represented by structural formula (II):

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is represented by structural formula (III):

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

m is 0; and

R 5 is selected from the group consisting of:

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:

m is 1; and

R 5 is cyclobutylene, cyclopentylene or cyclohexylene.

6. A compound selected from the group consisting of:

8-((5-((trans-4-(tert-butyl)cyclohexyl)oxy)naphthalen-2-yl)methyl)-8-azabicyclo[30.2.1]octane-3-carboxylic acid;

9-((5-((trans-4-(tert-butyl)cyclohexyl)oxy)naphthalen-2-yl)methyl)-9-azabicyclo[30.3.1]nonane-3-carboxylic acid;

3-(((5-((trans-4-(tert-butyl)cyclohexyl)oxy)naphthalen-2-yl)methyl)amino)-2,2-dimethylcyclobutanecarboxylic acid;

1-((5-((trans-4-(tert-butyl)cyclohexyl)oxy)naphthalen-2-yl)methyl)azetidine-3-carboxylic acid;

2-((5-((trans-4-(tert-butyl)cyclohexyl)oxy)naphthalen-2-yl)methyl)octahydrocyclopenta[c]pyrrole-5-carboxylic acid;

1-((5-((trans-4-(tert-butyl)cyclohexyl)oxy)naphthalen-2-yl)methyl)pyrrolidine-3-carboxylic acid;

3-(((5-((trans-4-(tert-butyl)cyclohexyl)oxy)naphthalen-2-yl)methyl)amino)cyclobutanecarboxylic acid;

1-((5-((trans-4-(tert-butyl)cyclohexyl)oxy)naphthalen-2-yl)methyl)azepane-4-carboxylic acid;

1-((5-((trans-4-(trifluoromethyl)cyclohexyl)oxy)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid;

1-((5-((cis-4-(trifluoromethyl)cyclohexyl)oxy)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid;

1-((5-((cis-4-isopropylcyclohexyl)oxy)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid;

1-((5-((cis-4-ethylcyclohexyl)oxy)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid;

1-((5-((trans-4-isopropylcyclohexyl)oxy)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid;

1-((5-((trans-4-ethylcyclohexyl)oxy)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid;

1-((5-((trans-4-methylcyclohexyl)oxy)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid;

1-((5-((4,4-dimethylcyclohexyl)oxy)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid;

1-((5-((trans-4-methylcyclohexyl)oxy)naphthalen-2-yl)methyl)azetidine-3-carboxylic acid;

1-((5-((trans-4-phenylcyclohexyl)oxy)naphthalen-2-yl)methyl)azetidine-3-carboxylic acid;

1-((5-((trans-4-ethylcyclohexyl)oxy)naphthalen-2-yl)methyl)azetidine-3-carboxylic acid;

1-((5-((trans-4-(trifluoromethyl)cyclohexyl)oxy)naphthalen-2-yl)methyl)azetidine-3-carboxylic acid;

1-((5-((trans-4-isopropylcyclohexyl)oxy)naphthalen-2-yl)methyl)azetidine-3-carboxylic acid;

1-((5-((trans-4-butylcyclohexyl)oxy)naphthalen-2-yl)methyl)azetidine-3-carboxylic acid;

1-((5-((trans-4-cyclopentylcyclohexyl)oxy)naphthalen-2-yl)methyl)azetidine-3-carboxylic acid;

1-((5-((trans-4-(tert-butyl)cyclohexyl)oxy)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid;

1-((5-(heptyloxy)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid;

9-((5-((cis-4-methylcyclohexyl)oxy)naphthalen-2-yl)methyl)-9-azabicyclo[3.3.1]nonane-3-carboxylic acid;

8-((5-((cis-4-methylcyclohexyl)oxy)naphthalen-2-yl)methyl)-8-azabicyclo[3.2.1]octane-3-carboxylic acid;

1-((5-((cis-4-methylcyclohexyl)oxy)naphthalen-2-yl)methyl)piperidine-4-carboxylic acid;

1-((5-(heptyloxy)naphthalen-1-yl)methyl)piperidine-4-carboxylic acid; and

1-((5-((trans-4-(tert-butyl)cyclohexyl)oxy)naphthalen-1-yl)methyl)piperidine-4-carboxylic acid;

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

8. A method of treating or reducing symptoms of a condition selected from the group consisting of multiple sclerosis, a chronic inflammatory disorder, asthma, an inflammatory neuropathy, arthritis, transplantation rejection, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, an ischemia-reperfusion injury, a solid tumor, a tumor metastasis, a vascular disease, a pain condition, an acute viral disease, an inflammatory bowel condition, insulin-dependent diabetes, non-insulin dependent diabetes, a fibrosis of the lung, and a malignancy of the lung in a mammal comprising administering to said mammal an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

9. The method of claim 8 , wherein the condition is multiple sclerosis.

10. The method of claim 8 , wherein the condition is rheumatoid arthritis.

11. The method of claim 8 , further comprising administering to said mammal an effective amount of one or more drugs selected from the group consisting of: a corticosteroid, a bronchodilator, an antiasthmatic, an antiinflammatory, an antirheumatic, an immunosuppressant, an antimetabolite, an immunomodulating agent, an antipsoriatic, and an antidiabetic.

12. A method of treating or reducing chronic pain in a mammal comprising administering to said mammal an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.

13. The method of claim 12 , wherein the chronic pain is inflammatory pain.

14. The method of claim 13 , wherein the chronic pain is neuropathic pain.